Blood cancer cell therapy shows promise in early trial says CGTC

By Gareth Macdonald

- Last updated on GMT

iStock/Alexandr Mitiuc
iStock/Alexandr Mitiuc

Related tags Leukemia

Early data from a trial of a cell therapy for blood cancer is positive according to the research arm of UK Cell and Gene Therapy Catapult (CGTC).

The therapy is based on patient derived T-cells that are modified to target cells that over express a protein encoded by the Wilms' tumor gene – WT1 – which are involved in diseases including acute myeloid leukemia (AML).

Interim analysis of data from a Phase I/II trial in patients suffering AML indicates that the modified cells have a good safety profile. The analysis also shows that the cells meet requirements for persistence and can survive and expand in patients.

CGTC CEO Keith Thompson said: “The progress of the WT1 TCR clinical trials supported by the positive DSMB review, is encouraging and we look forward to expanding these trials across the UK and Europe. Further results are expected during 2017​.”

The research is being conducted by Catapult Therapy TCR – a clinical trial organisation set up by CGTC - and partners UCL Business and Imperial Innovations.

The organisation has begun dosing a second cohort of AML patients.

The WT1 TCR therapy being used in the study is produced by Manchester, UK-based Cellular Therapeutics which was contracted by CGTC in August​.

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Related suppliers

Follow us


View more